Century Therapeutics, Inc. (IPSC)

Over the past six months, Century Therapeutics reported its full-year 2025 financial results and provided business updates in March 2026. The company participated in several investor conferences. Insider stock sales occurred in February 2026. In January 2026, the company secured a $135 million private placement to support its CNTY-813 program. In November 2025, Century Therapeutics announced its new beta islet program (CNTY-813) for Type 1 diabetes and reported its Q3 2025 financial results. The company also participated in the Piper Sandler 37th Annual Healthcare Conference in November 2025. Initial clinical data for its CD19-targeted CAR-iNK cells was anticipated in December 2025. The stock price increased by 326.47% from March 31, 2025, to March 30, 2026.

There is no information available to suggest demand seasonality for Century Therapeutics, Inc.'s products and services. Demand for its potential future products would primarily be driven by disease prevalence, clinical efficacy, regulatory approvals, and market access, rather than seasonal fluctuations.

Century Therapeutics is a clinical-stage biotechnology company focused on developing allogeneic cell therapies using genetically engineered induced pluripotent stem cells (iPSCs) for cancer and autoimmune diseases. The company's core business revolves around its proprietary iPSC platform and Allo-Evasion™ technology, which aims to engineer cell therapies that can evade the host immune system. Key pipeline candidates include CNTY-813 for Type 1 diabetes, CNTY-308 for B-cell-mediated autoimmune diseases, and CNTY-101 for B-cell driven autoimmune diseases.

Century Therapeutics is headquartered in Philadelphia, Pennsylvania, and has expanded its facilities within Philadelphia's uCity Square. It also has a manufacturing facility in Branchburg, New Jersey, a laboratory in Hamilton, Ontario, for glioblastoma research, and an innovation hub in Seattle to advance its iPSC platform.

Century Therapeutics has generally maintained a positive brand reputation, driven by its pipeline progress and financial activities. The company has received a "Moderate Buy" consensus rating from brokerages. Its stock performance has exceeded both the US Biotechs industry and the broader US Market. News coverage frequently highlights advancements in its clinical and preclinical programs, financial updates, and participation in investor conferences. Some analyses have noted concerns regarding the company's cash burn rate.

Century Therapeutics' ownership is distributed among institutional shareholders, insiders, and retail investors. Institutional ownership has been reported between approximately 5% and 50%. Insider ownership ranges from about 3.5% to 23.6%. Retail investors hold a significant portion, estimated between 62% and 89%. Major institutional owners include Point72 Asset Management, L.P., DAFNA Capital Management LLC, Vanguard Group Inc, Adage Capital Partners Gp, L.l.c., Two Sigma Investments, Lp, Spruce Street Capital LP, Renaissance Technologies Llc, Casdin Capital, LLC, and Acadian Asset Management Llc. Prominent individual or insider shareholders include Aktiengesellschaft Bayer, Versant Venture Capital VI LP, Fujifilm Cellular Dynamics Inc, Brent Pfeiffenberger, and Eli Casdin. Over the past six months, insider trading activity has shown more sales than purchases.